Analysis identifies high rates of hematological adverse events in CAR-T therapy patients, highlighting risks such as cytopenia and hemophagocytic lymphohistiocytosis.
Key Points
Hematological adverse events accounted for 11.75% of total adverse events, with cytopenia being notably high.
Data from over 47 million reports revealed significant risks including hemophagocytic lymphohistiocytosis and myelodysplastic syndrome.
Disproportion analysis methods showed varied hematological events among different CAR-T products, indicating treatment-specific risks.
Findings highlight the potential for early identification of serious hematological complications post-CAR-T therapy.